
The South African Health Products Regulatory Authority (SAHPRA) has presented South Africa’s approach to patient-focused drug development at the 2026 International Coalition of Medicines Regulatory Authorities (ICMRA) Summit in Seoul.
SAHPRA Chief Executive Officer Dr Boitumelo Semete-Makokotlela spoke in Session 3 of the Summit on 4 November 2026. She described how South Africa is working to place patients at the centre of drug development and to strengthen the regulatory frameworks that protect them.
The ICMRA Summit and Plenary took place from 3 to 6 November 2026 at the Conrad Seoul in the Republic of Korea. The event was hosted by the Ministry of Food and Drug Safety (MFDS). Around 30 countries participated, including heads and senior leaders from the European Medicines Agency (EMA), Japan’s Pharmaceuticals and Medical Devices Agency (PMDA), the US Food and Drug Administration (FDA), and other regulatory authorities. ICMRA comprises 43 regulatory agencies from 40 member countries together with the World Health Organization.
Session 3, co-chaired by Poland’s Office for Registration of Medicinal Products, Medical Devices and Biocidal Products (URPL) and the EMA, explored how regulators can bring the patient perspective into drug development. Presentations also came from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA), Swissmedic, Australia’s Therapeutic Goods Administration (TGA), the US FDA, Singapore’s Health Sciences Authority (HSA), China’s National Medical Products Administration (NMPA), and the European Commission’s DG SANTE.
The Summit’s first session addressed artificial intelligence in medicines regulation, co-chaired by Korea’s MFDS and Singapore’s HSA. The second session covered new approach methodologies and the 3Rs (Replacement, Reduction and Refinement) of animal testing, including a discussion of the ICMRA statement on the 3Rs published on 1 October 2026.
SAHPRA stated that its participation strengthens South Africa’s voice in global regulatory discussions and creates opportunities to learn from and contribute to international good practice. The authority said it will continue to engage with ICMRA and its members, apply lessons from Seoul to strengthen patient involvement in South Africa, and keep stakeholders informed as this work progresses.
Source: South African Health Products Regulatory Authority (SAHPRA), “SAHPRA Shares South Africa’s Patient-Focused Approach at the ICMRA Summit 2026 in Seoul”, 18 November 2026: https://www.sahpra.org.za/sahpra-shares-south-africas-patient-focused-approach-at-the-icmra-summit-2026-in-seoul/